Increased androgen receptor expression in estrogen receptor-positive/progesterone receptor-negative breast cancer

García, Ximena; Elía, Andrés; Galizzi, Lucrecia; May, María; Spengler, Eunice; Vázquez, Paula Martínez; Burruchaga, Javier; Rojas, Paola; Lanari, Claudia; Lamb, Caroline A.

doi:10.1007/s10549-020-05527-3

Cited by 11 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the median age of the enrolled patients was 46.5 years, which was consistent with the characteristics of early age of onset in China. Approximately 70-90% of luminal breast cancers and 60-70% of HER2-positive breast cancers express AR [42][43][44][45][46][47][48][49][50]. In our study, the proportion of breast cancers with AR expression was 86%, which matched the literature.…”

Section: Discussionsupporting

confidence: 90%

Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy

Zhang

Wang

et al. 2022

JPM

View full text Add to dashboard Cite

(1) Background: Neoadjuvant therapy is the main therapeutic strategy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients, and the combination of trastuzumab and pertuzumab (HP) has become a routine treatment. How to predict and screen patients who are less likely to respond to neoadjuvant therapy is the focus of research. The androgen receptor (AR) is a biomarker that is widely expressed in all breast cancer subtypes and is probably related to treatment response and prognosis. In this study, we investigated the relationship between AR expression and treatment response in HER2-positive breast cancer patients treated with HP neoadjuvant therapy. (2) Methods: We evaluated early breast cancer patients treated with HP neoadjuvant therapy from Jan. 2019 to Oct. 2020 at Peking University First Hospital Breast Cancer Center. The inclusion criteria were as follows: early HER2-positive breast cancer patients diagnosed by core needle biopsy who underwent both HP neoadjuvant therapy and surgery. We compared the clinical and pathological features between pathological complete response (pCR) and non-pCR patients. (3) Results: We included 44 patients. A total of 90.9% of patients received neoadjuvant therapy of taxanes, carboplatin, trastuzumab and pertuzumab (TCHP), and the total pCR rate was 50%. pCR was negatively related to estrogen receptor (ER) positivity (OR 0.075 [95% confidence interval (CI) 0.008–0.678], p = 0.021) and positively related to high expression levels of AR (OR 33.145 [95% CI 2.803–391.900], p = 0.005). We drew a receiver operating characteristic (ROC) curve to assess the predictive value of AR expression for pCR, and the area under the curve was 0.737 (95% CI 0.585–0.889, p = 0.007). The optimal cutoff of AR for predicting pCR was 85%. (4) Conclusion: AR is a potential marker for the prediction of pCR in HER2-positive breast cancer patients treated with HP neoadjuvant therapy.

show abstract

Section: Discussionsupporting

confidence: 90%

Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy

Zhang

Wang

et al. 2022

JPM

View full text Add to dashboard Cite

show abstract

“…androgen signaling have been tested with promising results. [34][35][36] Neoadjuvant therapies have been increasingly used in breast oncology not only as a clinical tool to allow tumor downstaging and less extensive surgeries, but also as a scientific tool to the evaluation of biomarkers and development of targeted therapies. In this case, the systemic therapy that will be offered will depend on disease staging and tumor biomarkers, such as HR evaluated on CNB.…”

Section: Discussionmentioning

confidence: 99%

Core Needle Biopsy Accuracy for Androgen Receptor Expression in Invasive Breast Cancer

Santos,

Frasson,

Silva

et al. 2023

Rev Bras Ginecol Obstet

View full text Add to dashboard Cite

Objective Breast cancer (BC) biomarkers, such as hormone receptors expression, are crucial to guide therapy in BC patients. Antiandrogens have been studied in BC; however, limited data are available on androgen receptor (AR) expression test methodology. We aim to report the core needle biopsy (CNB) accuracy for AR expression in BC. Methods Patients diagnosed with stage I-III invasive BC from a single institution were included. Androgen receptor expression was evaluated by immunohistochemistry (IHC) using 1 and 10% cutoff and the AR expression in surgical specimens (SS) was the gold standard. Kappa coefficients were used to evaluate the intraprocedural agreement. Results A total of 72 patients were included, with a mean age of 61 years old and 84% were Luminal A or B tumors. The prevalence of AR expression in all BC samples was 87.5% using a cutoff ≥ 10% in SS. With a cutoff value ≥ 1%, CNB had an accuracy of 95.8% (Kappa value = 0.645; 95% confidence interval [CI]: 0.272–1.000; p < 0.001) and 86.1% (Kappa value = 0.365; 95% CI: 0.052–0.679; p < 0.001) when ≥ 10% cutoff was used for AR positivity. Androgen receptor expression in CNB (cutoff ≥ 1%) had a sensitivity of 98.5%, specificity of 60%, positive predictive value of 97.0%, and a negative predictive value of 76.9% in the detection of AR expression in SS. Conclusion Core needle biopsy has good accuracy in evaluating AR expression in BC. The accuracy of CNB decreases with higher cutoff values for AR positivity.

show abstract

“…A large number of studies have found that AR is expressed in many breast cancer patients and common breast cancer cell lines, which makes AR become the most widely expressed receptor than ER, PR, and HER2 [9,10]. The latest research has found that AR plays an important role in the proliferation and invasion of AR+/ER-breast cancer cells, which suggests that AR antagonists can effectively inhibit the survival and growth of breast cancer cells [10,11].…”

Section: Discussionmentioning

confidence: 99%

AR Artificial Antagonist HC-1119 Regulated TNBC BT549 Cells Proliferation and Metastasis via PI3K/Akt/mTOR Signaling Pathway

Huang¹,

Zhang

Ren³

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Triple negative breast cancer (TNBC) was a specific refractory and aggressive malignancy subtype of breast cancer with high mortality. Our study aimed to explore the underlying molecular mechanism of androgen receptor (AR) antagonist HC-1119 on BT549 cells. Methods: AR, estrogen receptor (ER), progesterone receptor (PR), epidermal growth factor receptor 2 (HER2) were detected by western blotting in common breast cancer cell lines. The cell viability was detected by Cell Counting Kit-8 (CCK8) assay. The apoptotic percentage and cell cycle distribution were assessed by flow cytometry, the cells motility and invasion capability were analyzed by Transwell assay. The potential signaling pathway was explored by RNA-Seq and bioinformatics analysis in BT549 cells treated with HC-1119, and was determined by western blotting. Results: BT549 cells hardly expressed HER2, PR and ER, but highly expressed AR. HC-1119 significantly inhibited the AR expression. HC-1119 and bicalutamide both inhibited the cell proliferation in a concentration-dependent manner and in a time-dependent manner of BT549 cells. HC-1119 and bicalutamide could significantly increase the percentage of apoptosis and S-phase percentage of BT549 cells and reduced BT549 cells motility and invasion capabilities. RNA-Seq and Bioinformatics results showed that HC-1119 regulated BT549 cells proliferation via the PI3K/Akt/mTOR signaling pathway. Western blotting data convinced that HC-1119 could inhibit the expressions of p-mTOR, p-Akt, S6, p-S6 and P21.Conclusions: Our study revealed that the artificial AR antagonist HC-1119 inhibited BT549 cells cell proliferation, motility and invasion capabilities, induced cells apoptosis and arrested the cell cycle progression at the S phase. And HC-1119 may regulate cells proliferation via the PI3K/Akt/mTOR signaling pathway.

show abstract

Increased androgen receptor expression in estrogen receptor-positive/progesterone receptor-negative breast cancer

Cited by 11 publications

References 17 publications

Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy

Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy

Core Needle Biopsy Accuracy for Androgen Receptor Expression in Invasive Breast Cancer

AR Artificial Antagonist HC-1119 Regulated TNBC BT549 Cells Proliferation and Metastasis via PI3K/Akt/mTOR Signaling Pathway

Contact Info

Product

Resources

About